Meeting
2019 ASCO Annual Meeting
A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
Authors
Gary Edward Richardson
Monash University, Cabrini Hospital, Malvern, Australia
Gary Edward Richardson , Ulka N. Vaishampayan , Lin Lin , Viviana Bozon , Ai-Min Hui , Stephen K. Williamson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Conduct of Clinical Research
Clinical Trial Registration Number
NCT03690154
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS3150)
DOI
10.1200/JCO.2019.37.15_suppl.TPS3150
Abstract #
TPS3150
Poster Bd #
140a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
First Author: Todd Michael Bauer
Poster
2012 ASCO Annual Meeting
Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).
First Author: Paul Hamberg
Poster
2016 ASCO Annual Meeting
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.
First Author: Johanna C. Bendell
Poster
2015 ASCO Annual Meeting
A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
First Author: Gary K. Schwartz